Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Mar 04, 2016	Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results SOLANA BEACH, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the fourth quarter and full year 2015 on Thursday,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Year End 2015 Financial Results 15.7 KB
Toggle Summary Mar 03, 2016	Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts NDA Preparation Initiates as EVK-001 Nears Phase 3 Study Completion	View HTML Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 15.9 KB
Toggle Summary Mar 01, 2016	Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001	View HTML Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 16.9 KB
Toggle Summary Feb 17, 2016	Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 Clinical Data Support Cardiac Safety of EVK-001	View HTML Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 16.2 KB
Toggle Summary Nov 12, 2015	Evoke Pharma Reports Third Quarter 2015 Results Enhanced Financial Strength and Further Progressed Trial Enrollment	View HTML Evoke Pharma Reports Third Quarter 2015 Results 26.1 KB
Toggle Summary Nov 10, 2015	Evoke to Participate in the Brean Capital 2015 Life Sciences Summit SOLANA BEACH, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , R.Ph., President and CEO will be participating in the Brean Capital 2015 Life	View HTML Evoke to Participate in the Brean Capital 2015 Life Sciences Summit 15.3 KB
Toggle Summary Nov 05, 2015	Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results SOLANA BEACH, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results 11.9 KB
Toggle Summary Oct 07, 2015	Evoke Pharma Strengthens Financial Position Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)	View HTML Evoke Pharma Strengthens Financial Position 16.9 KB
Toggle Summary Sep 28, 2015	Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 150 Patients Enrolled in Phase 3 Clinical Trial	View HTML Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 15.7 KB
Toggle Summary Sep 15, 2015	U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs	View HTML U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 18.7 KB